tqb2825
mAbexperimentalBi-specific
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Mar 22, 2022 (NCT05489276)
Timeline
Indications
Mechanism of action
CD3E agonist
- B-lymphocyte antigen CD20BINDING AGENT
CD20
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07187960 | Phase 3 | Nov 30, 2025 | Government of China |
| NCT07110194 | Phase 1 | Sep 30, 2025 | Government of China |
| NCT06829771 | Phase 1/Phase 2 (Phase 2) | Apr 23, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06854445 | Phase 2 | Mar 12, 2025 | Government of China |
| NCT05489276 | Phase 1 | Mar 22, 2022 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 3 | 3 | 3 | 2025 |
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 2 | 2 | 2 | 2022 |
2 organizations
Page 1 / 1